Probatebeta
Target

SLC5A2

Sodium/glucose cotransporter 2

As of the edition of 20 October 2026, SLC5A2 (sodium/glucose cotransporter 2, UniProt P31639) has 17 drugs tested at it and 22 companies on the list, 3 on route A and 9 on route B.

Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.

The protein

UniProt
P31639
How well studied
Drug target: an approved drug acts on it
Where it sits in the cell
At a membrane
Solved structures
12
Disease areas
Nutrition and metabolism; Hormones; Heart and blood vessels; Urinary and reproductive; Pregnancy and women's health; Immune system; Digestive system; Cancer
Registered trials of its drugs
1,205

Drugs at this target

StatusCount
Marketed9
Active3
Went quiet3
Stopped2
Total17
DrugStatusFurthest phaseUS protection
DapagliflozinMarketedPhase 4Ends 2029
EmpagliflozinMarketedPhase 4Ends 2028
Canagliflozin anhydrousMarketedPhase 4Ends 2029
SotagliflozinMarketedPhase 4Ends 2030
IpragliflozinStoppedPhase 4none listed
ErtugliflozinMarketedPhase 4Ends 2031
EnavogliflozinActivePhase 4none listed
HenagliflozinActivePhase 4none listed
Remogliflozin etabonateWent quietPhase 2none listed
BexagliflozinMarketedPhase 4Ends 2032
LicogliflozinStoppedPhase 2none listed
Tofogliflozin anhydrousMarketedPhase 4none listed

12 of 17 drugs, the most tested first.

Companies at this target

Where the company standsCompanies
Route A3
Route B9
Engaged4
Undetermined6
Total on the list22
Three companies on route A or B, with the route only
CompanyRoute
SanofiRoute B
AstraZenecaRoute B
Merck & Co.Route B

The other 19 companies at SLC5A2

In the product

22 companies in all; 19 are not named here, and no score is.

See the 22 companies at SLC5A2, ranked, with the facts behind eachRequest access. Nothing is shown until you do.

More drugs at SLC5A2

Other targets in nutrition and metabolism

Companies holding approvals at SLC5A2